A Review of Inflammation and Fibrosis: Implications for the Pathogenesis of Peyronie's Disease

Overview

Journal World J Urol

Specialty Urology

Date 2019 Jun 14

PMID 31190155

Citations 18

Authors

Darshan P Patel

Michael B Christensen

James M Hotaling

Alexander W Pastuszak

Affiliations

Soon will be listed here.

Abstract

Peyronie's disease (PD) is a superficial fibrosing disorder that causes penile deformity and can interfere with sexual intercourse and reproduction, as well as diminish quality of life. While the exact mechanism of PD is still being investigated, there is likely a genetic component to the predisposition to penile plaque formation. Ultimately, however, perturbations in normal wound healing and aberrant deposition of extracellular matrix components lead to fibrotic tissue deposition. Fibrosis in PD is regulated by a complex pathway of inflammatory and fibrotic mediators. Currently there are no treatments for PD that address an underlying cause or disease progression. In this review, we provide an overview of the known inflammatory and fibrotic mediators of PD and explore the pathophysiology of other human superficial fibrosing disorders to develop further insights into PD.

Citing Articles

[New "conservative" treatments for Peyronie's disease-real alternatives or expensive pastime?].

Schlager D, Leiber-Caspers C Urologie. 2024; 63(11):1097-1102.

PMID: 39384594 DOI: 10.1007/s00120-024-02453-w.

The Promise of Artificial Intelligence in Peyronie's Disease.

Furtado T, Osadchiy V, Eleswarapu S Curr Urol Rep. 2024; 26(1):3.

PMID: 39305366 PMC: 11416409. DOI: 10.1007/s11934-024-01233-5.

Unveiling the molecular Hallmarks of Peyronie's disease: a comprehensive narrative review.

Sahin A, Babayev H, Cirigliano L, Preto M, Falcone M, Altintas E Int J Impot Res. 2024; 36(8):801-808.

PMID: 38454161 DOI: 10.1038/s41443-024-00845-2.

[Current treatment concepts for Peyronie's disease].

Hinz J, Soave A, Cremers J Urologie. 2023; 62(12):1332-1342.

PMID: 37922029 DOI: 10.1007/s00120-023-02213-2.

The prevalence and topographic distribution of penile calcification in a large cohort: a retrospective cross-sectional study.

Baran C, Culha M, Bayraktarli R, Ozgur B, Bayraktar A, Oktem C Int J Impot Res. 2023; 36(6):576-580.

PMID: 37660216 DOI: 10.1038/s41443-023-00758-6.

References

Giannandrea M, Parks W . Diverse functions of matrix metalloproteinases during fibrosis. Dis Model Mech. 2014; 7(2):193-203. PMC: 3917240. DOI: 10.1242/dmm.012062. View

Davila H, Magee T, Zuniga F, Rajfer J, Gonzalez-Cadavid N . Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. Urology. 2005; 65(4):645-8. DOI: 10.1016/j.urology.2005.01.010. View

Bilgutay A, Pastuszak A . PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT. Curr Sex Health Rep. 2015; 7(2):117-131. PMC: 4535719. DOI: 10.1007/s11930-015-0045-y. View

Willscher M, Cwazka W, Novicki D . The association of histocompatibility antigens of the B7 cross-reacting group with Peyronie's disease. J Urol. 1979; 122(1):34-5. DOI: 10.1016/s0022-5347(17)56238-2. View

Bivalacqua T, Champion H, Hellstrom W . Implications of nitric oxide synthase isoforms in the pathophysiology of Peyronie's disease. Int J Impot Res. 2002; 14(5):345-52. DOI: 10.1038/sj.ijir.3900872. View

Dolmans G, de Bock G, Werker P . Dupuytren diathesis and genetic risk. J Hand Surg Am. 2012; 37(10):2106-11. DOI: 10.1016/j.jhsa.2012.07.017. View

Van de Water L . Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie's disease. J Urol. 1997; 157(1):306-10. DOI: 10.1097/00005392-199701000-00103. View

Derynck R, Zhang Y . Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958):577-84. DOI: 10.1038/nature02006. View

El-Sakka A, Hassoba H, Pillarisetty R, Dahiya R, Lue T . Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol. 1997; 158(4):1391-4. View

10.

Simeon C, Fonollosa V, Vilardell M, Ordi J, Solans R, Lima J . Impotence and Peyronie's disease in systemic sclerosis. Clin Exp Rheumatol. 1994; 12(4):464. View

11.

Badalamente M, Sampson S, HURST L, Dowd A, Miyasaka K . The role of transforming growth factor beta in Dupuytren's disease. J Hand Surg Am. 1996; 21(2):210-5. DOI: 10.1016/S0363-5023(96)80102-X. View

12.

Nugteren H, Nijman J, de Jong I, van Driel M . The association between Peyronie's and Dupuytren's disease. Int J Impot Res. 2011; 23(4):142-5. DOI: 10.1038/ijir.2011.18. View

13.

Higgins D, Kimura K, Bernhardt W, Shrimanker N, Akai Y, Hohenstein B . Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest. 2007; 117(12):3810-20. PMC: 2082142. DOI: 10.1172/JCI30487. View

14.

Gonzalez-Cadavid N, Magee T, Ferrini M, Qian A, Vernet D, Rajfer J . Gene expression in Peyronie's disease. Int J Impot Res. 2002; 14(5):361-74. DOI: 10.1038/sj.ijir.3900873. View

15.

Amara N, Goven D, Prost F, Muloway R, Crestani B, Boczkowski J . NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax. 2010; 65(8):733-8. PMC: 3004009. DOI: 10.1136/thx.2009.113456. View

16.

Sasaki K, Hattori T, Fujisawa T, Takahashi K, Inoue H, Takigawa M . Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J Biochem. 1998; 123(3):431-9. DOI: 10.1093/oxfordjournals.jbchem.a021955. View

17.

Meng X, Nikolic-Paterson D, Lan H . TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016; 12(6):325-38. DOI: 10.1038/nrneph.2016.48. View

18.

Poli G, Parola M . Oxidative damage and fibrogenesis. Free Radic Biol Med. 1997; 22(1-2):287-305. DOI: 10.1016/s0891-5849(96)00327-9. View

19.

Bayat A, Alansar A, Hajeer A, Shah M, Watson J, Stanley J . Genetic susceptibility in Dupuytren's disease: lack of association of a novel transforming growth factor beta(2) polymorphism in Dupuytren's disease. J Hand Surg Br. 2002; 27(1):47-9. DOI: 10.1054/jhsb.2001.0689. View

20.

Pardo A, Selman M . Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc. 2006; 3(4):383-8. DOI: 10.1513/pats.200601-012TK. View